Injectable Drugs for Type-2 Diabetes Industry - Regional Synopsis
North America industry is estimated to hold largest revenue share by 2037, backed by increasing prevalence of type 2 diabetes and obesity in the region.
Currently, North America region holds the maximum market share on the back of increasing prevalence of type 2 diabetes and obesity in the region along with the presence of world’s leading contributor, USA, in this field. Asian countries are expected to show significant growth owing to the initiatives taken by local government and health organizations to spread awareness about diabetes and its management using drugs and devices.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Injectable Drugs for Type-2 Diabetes Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.
Injectable Drugs for Type-2 Diabetes Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.
North America industry is estimated to hold largest revenue share by 2037, backed by increasing prevalence of type 2 diabetes and obesity in the region.
The major players in the market are AstraZeneca Plc., GlaxoSmithKline Plc., Merck & Co., Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novo Nordisk A/S, Sanofi, Eli Lilly and Company, and others.
